Product logins

Find logins to all Clarivate products below.


Emerging Vaccines – Epidemiology – Epidemiology – Emerging Vaccines- Mature Markets

Clarivate Epidemiology’s coverage of emerging vaccines comprises epidemiological estimates of eligible populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the eligible population rate per 1,000 persons for each country, as well as annualized counts projected to the national population.

All populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

The full list of the populations that we forecast for emerging vaccines are as follows:

  • HBV vaccine-eligible population, pediatrics.
  • HBV vaccine-eligible population, adolescents.
  • HBV vaccine-eligible population, adults.
  • HBV vaccine newly eligible population, pediatrics.
  • HBV vaccine newly eligible population, adolescents.
  • HBV vaccine newly eligible population, adults.
  • HPV vaccine-eligible population, adolescent males.
  • HPV vaccine-eligible population, adolescent females.
  • HPV vaccine-eligible population, adult males.
  • HPV vaccine-eligible population, adult females.
  • HPV vaccine newly eligible population, adolescent males.
  • HPV vaccine newly eligible population, adolescent females.
  • HPV vaccine newly eligible population, adult males.
  • HPV vaccine newly eligible population, adult females.
  • Influenza vaccine total eligible population.
  • Pneumococcal vaccine total eligible population.
  • Pneumococcal vaccine newly eligible population.
  • Shingles vaccine total eligible population.
  • Shingles vaccine newly eligible population.
  • Meningococcal ACWY vaccine total eligible population.
  • Meningococcal ACWY vaccine newly eligible population.
  • Meningococcal B vaccine total eligible population.
  • Meningococcal B vaccine newly eligible population.
  • RSV vaccine-eligible population, pediatrics.
  • RSV vaccine-eligible population, adults.
  • RSV vaccine-eligible population, maternal.
  • RSV vaccine newly eligible population, pediatrics.
  • RSV vaccine newly eligible population, adults.
  • RSV vaccine newly eligible population, maternal.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Insomnia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Insomnia (US)
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…